📣 VC round data is live. Check it out!

Biomea Fusion Valuation Multiples

Discover revenue and EBITDA valuation multiples for Biomea Fusion and similar public comparables like Adocia, Actinogen Medical, Inovio Pharmaceuticals, Faron Pharmaceuticals and more.

Biomea Fusion Overview

About Biomea Fusion

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.


Founded

2017

HQ

United States

Employees

106

Financials (LTM)

Revenue:
EBITDA: ($78M)

EV

$70M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Biomea Fusion Financials

Biomea Fusion reported last 12-month revenue of — and negative EBITDA of ($78M).

In the same LTM period, Biomea Fusion generated — in gross profit, ($78M) in EBITDA losses, and had net loss of ($65M).

Revenue (LTM)


Biomea Fusion P&L

In the most recent fiscal year, Biomea Fusion reported revenue of and EBITDA of ($80M).

Biomea Fusion is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.

See analyst estimates for Biomea Fusion
LTMLast FY202320242025202620272028
EBITDA($78M)($80M)($125M)($142M)($80M)
Net Profit($65M)($62M)($117M)($138M)($62M)

Financial data powered by Morningstar, Inc.

Biomea Fusion Stock Performance

Biomea Fusion has current market cap of $114M, and enterprise value of $70M.

Market Cap Evolution


Biomea Fusion's stock price is $1.58.

Biomea Fusion share price increased by 15.8% in the last 30 days, and by 9.4% in the last year.

Biomea Fusion has an EPS (earnings per share) of $-0.85.

See more trading valuation data for Biomea Fusion
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$70M$114M1.0%15.8%17.6%9.4%$-0.85

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Biomea Fusion Valuation Multiples

Biomea Fusion trades at (0.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for Biomea Fusion

EV / Revenue (LTM)


Biomea Fusion Financial Valuation Multiples

As of May 13, 2026, Biomea Fusion has market cap of $114M and EV of $70M.

Biomea Fusion has a P/E ratio of (1.8x).

LTMLast FY202320242025202620272028
EV/EBITDA(0.9x)(0.9x)(0.6x)(0.5x)(0.9x)
EV/EBIT(0.9x)(0.9x)(0.6x)(0.5x)(0.9x)
P/E(1.8x)(1.8x)(1.0x)(0.8x)(1.8x)
EV/FCF(1.1x)(1.0x)(0.7x)(0.6x)(1.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Biomea Fusion Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Biomea Fusion Margins & Growth Rates

Biomea Fusion decreased EBITDA by 12% in the last fiscal year.

See estimated margins and future growth rates for Biomea Fusion

Biomea Fusion Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
EBITDA Growth(12%)14%(44%)(12%)
EBIT Growth(8%)14%(44%)(8%)
Net Profit Growth14%18%(55%)14%
FCF Growth(22%)20%(41%)(22%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Biomea Fusion Operational KPIs

Biomea Fusion's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.

Access forward-looking KPIs for Biomea Fusion
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$0.8M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Biomea Fusion Competitors

Biomea Fusion competitors include Adocia, Actinogen Medical, Inovio Pharmaceuticals, Faron Pharmaceuticals, PepGen, Nykode Therapeutics, Cardiff Oncology, Kalaris Therapeutics, Fractyl Health and Rani Therapeutics.

Most Biomea Fusion public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Adocia23.0x14.5x(5.7x)(6.2x)
Actinogen Medical31.3x(8.4x)
Inovio Pharmaceuticals1008.5x16.4x(0.8x)
Faron Pharmaceuticals336.4x529.2x(5.6x)(5.4x)
PepGen0.2x
Nykode Therapeutics(3.5x)(1.7x)
Cardiff Oncology92.2x109.3x(1.1x)
Kalaris Therapeutics0.2x0.1x

This data is available for Pro users. Sign up to see all Biomea Fusion competitors and their valuation data.

Start Free Trial

Biomea Fusion Funding History

Before going public, Biomea Fusion raised $56M in total equity funding, across 1 round.


Biomea Fusion Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-21Series AAisling Capital; Boxer Capital; Cormorant Asset Management; Janus Henderson Investors; Logos Capital; Point Sur Investors; Rock Springs Capital; RTW Investments$56MBiomea Fusion, Inc. (BMEA) is a clinical-stage biopharmaceutical company developing oral covalent small molecule drugs targeting key cancer drivers to create irreversible covalent bonds with highly mutated kinases and other protein targets. The specified Series B funding round in June 2021 raised approximately $56 million led by Cormorant Asset Management, with participation from Aisling Capital, Boxer Capital, Janus Henderson Investors, Logos Capital, Point Sur Investors, Rock Springs Capital, and RTW Investments. The company went public later. Competitive context includes peers in biotech with negative returns on assets and equity, high volatility, and focus on healthcare investments.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Biomea Fusion

When was Biomea Fusion founded?Biomea Fusion was founded in 2017.
Where is Biomea Fusion headquartered?Biomea Fusion is headquartered in United States.
How many employees does Biomea Fusion have?As of today, Biomea Fusion has over 106 employees.
Who is the CEO of Biomea Fusion?Biomea Fusion's CEO is Michael J. M. Hitchcock.
Is Biomea Fusion publicly listed?Yes, Biomea Fusion is a public company listed on Nasdaq.
What is the stock symbol of Biomea Fusion?Biomea Fusion trades under BMEA ticker.
When did Biomea Fusion go public?Biomea Fusion went public in 2021.
Who are competitors of Biomea Fusion?Biomea Fusion main competitors include Adocia, Actinogen Medical, Inovio Pharmaceuticals, Faron Pharmaceuticals, PepGen, Nykode Therapeutics, Cardiff Oncology, Kalaris Therapeutics, Fractyl Health, Rani Therapeutics.
What is the current market cap of Biomea Fusion?Biomea Fusion's current market cap is $114M.
Is Biomea Fusion profitable?No, Biomea Fusion is not profitable.
What is the current EBITDA of Biomea Fusion?Biomea Fusion has negative EBITDA and is not profitable.
What is the current EV/EBITDA multiple of Biomea Fusion?Current EBITDA multiple of Biomea Fusion is (0.9x).
What is the current FCF of Biomea Fusion?Biomea Fusion's last 12 months FCF is ($66M).
What is the current EV/FCF multiple of Biomea Fusion?Current FCF multiple of Biomea Fusion is (1.1x).
How many companies Biomea Fusion has acquired to date?Biomea Fusion hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Biomea Fusion has invested to date?Biomea Fusion hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Biomea Fusion

Lists including Biomea Fusion

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial